Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents.

Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents.

Item
http://www.wikidata.org/entity/Q45293401
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive reviewGuidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).A delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration.Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy.One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study.Photodynamic therapy: current role in the treatment of chorioretinal conditionsSubretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration.Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration.Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factorsAnti-vascular endothelial growth factor in age-related macular degeneration: puzzle or a silent beginning!Development of Multigenic Lentiviral Vectors for Cell-Specific Expression of Antiangiogenic miRNAs and Protein Factors.Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy.Expression of cytokines on the iris of patients with neovascular glaucoma.Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan.
P2860

Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents.

Item
http://www.wikidata.org/entity/Q45293401
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Combination therapy for neovas ...... othelial growth factor agents.
@en
Combination therapy for neovas ...... othelial growth factor agents.
@nl
type
label
Combination therapy for neovas ...... othelial growth factor agents.
@en
Combination therapy for neovas ...... othelial growth factor agents.
@nl
prefLabel
Combination therapy for neovas ...... othelial growth factor agents.
@en
Combination therapy for neovas ...... othelial growth factor agents.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Combination therapy for neovas ...... dothelial growth factor agents
@en
P2093
P304
P31
P356
10.1016/J.OPHTHA.2013.03.016
P433
P478
P50
P577
P5875
P698
P921